BR112018072948A2 - composição farmacêutica líquida, e, método para a estabilização de um antibiótico glicopeptídeo em uma solução farmacêutica líquida. - Google Patents

composição farmacêutica líquida, e, método para a estabilização de um antibiótico glicopeptídeo em uma solução farmacêutica líquida.

Info

Publication number
BR112018072948A2
BR112018072948A2 BR112018072948-5A BR112018072948A BR112018072948A2 BR 112018072948 A2 BR112018072948 A2 BR 112018072948A2 BR 112018072948 A BR112018072948 A BR 112018072948A BR 112018072948 A2 BR112018072948 A2 BR 112018072948A2
Authority
BR
Brazil
Prior art keywords
liquid pharmaceutical
stabilizing
glycopeptide antibiotic
pharmaceutical composition
solution
Prior art date
Application number
BR112018072948-5A
Other languages
English (en)
Inventor
KESER Sabina
Jasprica Ivona
Le-Cunff Jerome
Original Assignee
Xellia Pharmaceuticals Aps
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xellia Pharmaceuticals Aps filed Critical Xellia Pharmaceuticals Aps
Publication of BR112018072948A2 publication Critical patent/BR112018072948A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

são divulgadas aqui formulações líquidas de antibióticos glicopeptídeos ou seus sais farmaceuticamente aceitáveis, em que o antibiótico glicopeptídeo é selecionado a partir de vancomicina, telavancina, oritavancina, teicoplanina e dalbavancina. as ditas formulações são adequadas como soluções de infusão ou como um concentrado para a preparação de soluções de infusão.
BR112018072948-5A 2016-05-09 2017-05-04 composição farmacêutica líquida, e, método para a estabilização de um antibiótico glicopeptídeo em uma solução farmacêutica líquida. BR112018072948A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662333357P 2016-05-09 2016-05-09
US62/333,357 2016-05-09
PCT/EP2017/060653 WO2017194385A1 (en) 2016-05-09 2017-05-04 Stabilized glycopeptide antibiotic formulations

Publications (1)

Publication Number Publication Date
BR112018072948A2 true BR112018072948A2 (pt) 2019-02-19

Family

ID=58745200

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018072948-5A BR112018072948A2 (pt) 2016-05-09 2017-05-04 composição farmacêutica líquida, e, método para a estabilização de um antibiótico glicopeptídeo em uma solução farmacêutica líquida.

Country Status (20)

Country Link
US (1) US10729708B2 (pt)
EP (1) EP3454883A1 (pt)
JP (1) JP6946343B2 (pt)
KR (1) KR20190005940A (pt)
CN (1) CN109069580A (pt)
AR (1) AR109454A1 (pt)
AU (1) AU2017262943B2 (pt)
BR (1) BR112018072948A2 (pt)
CA (1) CA3021935A1 (pt)
CL (1) CL2018003147A1 (pt)
CO (1) CO2018011701A2 (pt)
EA (1) EA201892413A1 (pt)
IL (1) IL262796A (pt)
JO (2) JOP20170111B1 (pt)
MX (1) MX2018013584A (pt)
SA (1) SA518400392B1 (pt)
SG (1) SG11201809908TA (pt)
TW (2) TWI769694B (pt)
UY (1) UY37233A (pt)
WO (1) WO2017194385A1 (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015341763B2 (en) 2014-11-06 2019-01-17 Xellia Pharmaceuticals Aps Glycopeptide compositions
WO2021231361A1 (en) * 2020-05-11 2021-11-18 Anovent Pharmaceutical (U.S.), Llc Pharmaceutical formulation containing active metabolites of remdesivir for inhalation
EP4014969A1 (en) 2020-12-16 2022-06-22 EVER Valinject GmbH Aqueous solution
EP4014965A1 (en) 2020-12-16 2022-06-22 EVER Valinject GmbH Aqueous solution
CN115804832A (zh) * 2021-09-14 2023-03-17 海南普利制药股份有限公司 一种万古霉素水溶液组合物
WO2023171588A1 (ja) * 2022-03-08 2023-09-14 国立大学法人大阪大学 抗菌薬を含有するｐｌｇａ製剤
WO2023211501A1 (en) * 2022-04-26 2023-11-02 Hikma Pharmaceuticals Usa Inc. Stable, ready-to-administer aqueous formulations of dalbavancin
GB202207344D0 (en) 2022-05-19 2022-07-06 Arecor Ltd Novel composition
GB202207345D0 (en) 2022-05-19 2022-07-06 Arecor Ltd Novel composition
CN117618338A (zh) * 2022-08-16 2024-03-01 海南普利制药股份有限公司 一种稳定的奥利万星药物水溶液及其制备方法
WO2024079223A1 (en) * 2022-10-12 2024-04-18 Xellia Pharmaceuticals Aps Liquid dalbavancin composition
WO2024079224A1 (en) * 2022-10-12 2024-04-18 Xellia Pharmaceuticals Aps Liquid dalbavancin composition

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1278549A (en) * 1916-12-16 1918-09-10 J E Simmons Nut and bolt lock.
US4670258A (en) 1984-02-10 1987-06-02 Vanderbilt University Storable prepackaged aqueous solutions of vancomycin
US4885275A (en) 1987-10-15 1989-12-05 Eli Lilly And Company Vancomycin-HCL solutions and the lyophilization thereof
WO1997019690A1 (en) 1995-12-01 1997-06-05 Eli Lilly And Company Stable vancomycin hydrochloride solutions
JPH1180021A (ja) 1997-09-02 1999-03-23 Kayaku:Kk バンコマイシン注射剤
CN1223378C (zh) 2000-05-02 2005-10-19 施万制药 含有糖肽抗生素和环糊精的药物组合物
WO2001083520A2 (en) * 2000-05-02 2001-11-08 Theravance,Inc Polyacid glycopeptide derivatives
ATE402951T1 (de) * 2000-05-02 2008-08-15 Theravance Inc Verfahren zur reduktiven alkylierung von glykopeptiden
UA82824C2 (uk) * 2000-06-21 2008-05-26 К'Юбіст Фармасьютікалз, Інк. Композиція і спосіб поліпшення перорального всмоктування протимікробних засобів
UA75083C2 (uk) * 2000-06-22 2006-03-15 Тераванс, Інк. Похідні глікопептидфосфонатів
US7034013B2 (en) * 2001-03-20 2006-04-25 Cydex, Inc. Formulations containing propofol and a sulfoalkyl ether cyclodextrin
US7119061B2 (en) * 2002-11-18 2006-10-10 Vicuron Pharmaceuticals, Inc. Dalbavancin compositions for treatment of bacterial infections
EP1678211A4 (en) * 2003-10-31 2008-04-02 Univ Kansas SULFOALKYL ETHER-ALKYL ETHER CYCLODEXTRINS DERIVATIVES
AU2006213441B2 (en) 2005-02-14 2011-12-01 Venus Remedies Limited Parenteral combination therpy for infective conditions with drug resistant bacterium
CN1857716A (zh) * 2006-03-14 2006-11-08 浙江大学 注射用盐酸万古霉素及其制备方法
JP2008201778A (ja) 2007-01-25 2008-09-04 Mochida Pharmaceut Co Ltd バンコマイシン液状製剤
BRPI0816662A2 (pt) 2007-09-12 2017-06-13 Targanta Therapeutics Corp método de inibição de clostridium difficile pela administração de oritavancina
US7635773B2 (en) 2008-04-28 2009-12-22 Cydex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions
CN102755629A (zh) * 2012-08-02 2012-10-31 上海瑞创医药科技有限公司 与万古霉素形成抗菌增效包合物的组分和制备方法及其应用
RU2018135921A (ru) 2012-11-29 2019-02-05 Инсмед Инкорпорейтед Стабилизированные составы ванкомицина
CN104043104B (zh) 2013-03-15 2018-07-10 浙江创新生物有限公司 含盐酸万古霉素的喷雾干粉及其工业化制备方法
US9616098B2 (en) 2013-05-30 2017-04-11 Scidose, Llc Formulations of vancomycin
AU2015341763B2 (en) * 2014-11-06 2019-01-17 Xellia Pharmaceuticals Aps Glycopeptide compositions
EA036750B1 (ru) 2016-01-08 2020-12-16 Гуфик Байосайенсиз Лимитед Лиофилизированная парентеральная композиция тигециклина и способ ее приготовления
CA3014294A1 (en) * 2016-02-18 2017-08-24 Melinta Therapeutics, Inc. Oritavancin formulations

Also Published As

Publication number Publication date
JP6946343B2 (ja) 2021-10-06
JP2019518733A (ja) 2019-07-04
MX2018013584A (es) 2019-04-01
WO2017194385A1 (en) 2017-11-16
US20190175632A1 (en) 2019-06-13
IL262796A (en) 2018-12-31
EA201892413A1 (ru) 2019-05-31
EP3454883A1 (en) 2019-03-20
AR109454A1 (es) 2018-12-12
CN109069580A (zh) 2018-12-21
TW202133875A (zh) 2021-09-16
JOP20170111B1 (ar) 2022-03-14
KR20190005940A (ko) 2019-01-16
AU2017262943A1 (en) 2018-11-22
SG11201809908TA (en) 2018-12-28
CA3021935A1 (en) 2017-11-16
US10729708B2 (en) 2020-08-04
UY37233A (es) 2018-01-02
CO2018011701A2 (es) 2019-02-08
SA518400392B1 (ar) 2022-05-09
CL2018003147A1 (es) 2018-12-28
TWI769694B (zh) 2022-07-01
TWI772296B (zh) 2022-08-01
AU2017262943B2 (en) 2020-05-14
JOP20220039A1 (ar) 2023-01-30
TW201740955A (zh) 2017-12-01

Similar Documents

Publication Publication Date Title
BR112018072948A2 (pt) composição farmacêutica líquida, e, método para a estabilização de um antibiótico glicopeptídeo em uma solução farmacêutica líquida.
BR112017028413A2 (pt) peptídeos antimicrobianos estabilizados
MX2022001540A (es) Composiciones farmaceuticas y metodos para contrarrestar la cardiotoxicidad inducida por quimioterapia.
BR112018004532A2 (pt) uso de akkermansia pasteurizado para o tratamento de distúrbios metabólicos
EA201890731A1 (ru) Модуляторы корового белка гепатита b
BR112018077457A2 (pt) composição farmacêutica para evitar ou tratar hiperinsulinismo congênito e seu método, hipoglicemia e seu método, síndrome metabólica e seu método e peptídeo isolado
WO2017083431A3 (en) Hydroxypyridinone and hydroxypyrimidinone based compounds for treating bacterial infections
BR112017000246A2 (pt) composto, sal farmaceuticamente aceitável de um composto, composição farmacêutica, e, uso de um composto ou de um sal
BR112015011697A2 (pt) antibióticos macrocíclicos de amplo espectro
BR112017006113A2 (pt) combinações sinérgicas de auristatina
WO2019032936A8 (en) LINCONSAMIDE ANTIBIOTICS AND USES THEREOF
BR112018010255A2 (pt) antibióticos macrocíclicos de amplo espectro
BR112017012406A2 (pt) formulação com relação fixa de insulina glargina/lixisenatida
EP3604304A4 (en) PYRROLO-PYRIDINE DERIVATIVE COMPOUND, METHOD OF MANUFACTURING AND PHARMACEUTICAL COMPOSITION THEREOF FOR THE PREVENTION OR TREATMENT OF PROTEIN KINASE-RELATED DISEASES
BR112019000453A2 (pt) combinação de ceftibuteno e ácido clavulânico para uso no tratamento de infecções bacterianas
BR112018010267A2 (pt) antibióticos macrocíclicos de amplo espectro
BR112017005828A2 (pt) métodos para tratar ou prevenir uma infecção respiratória, copd e uma exacerbação de copd e para selecionar um inibidor de sinalização notch 3 e/ou notch4, usp de um inibidor de sinalização de notch 3 e/ou notch 4, inibidor de sinalização de notch 3 e/ou notch 4, e, composição farmacêutica.
BR112019018615A2 (pt) compostos antimicrobianos, composições e usos dos mesmos
BR112018014723A2 (pt) fantasmas bacterianos para o tratamento de câncer
MX2017010837A (es) Dosis y metodos para administrar telavancina.
BR112018070929A2 (pt) peptídeos bioativos peguilados e seu uso
BR112018068462A2 (pt) composto, composição farmacêutica, método para tratar uma infecção bacteriana, e, uso de um composto.
BR112019001130A2 (pt) uso de lactama e composição farmacêutica
BR112018068794A2 (pt) composição para a prevenção de infecção intramamária e método de prevenção de infecção intramamária
BR112016018681A2 (pt) implante que compreende fgf-18

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2669 DE 03-03-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.